Journal
SHOCK
Volume 50, Issue 5, Pages 538-544Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SHK.0000000000001123
Keywords
Cardiogenic shock; endothelium; mortality; ST-elevation myocardial infarction; syndecan-1; thrombomodulin
Funding
- Righospitalets Forskningsfond [07IO]
- Forskningspuljen ml RH og OUH [13-A750, 25-A1365]
- Danish Heart Foundation (Hjerteforeningen) [A6024]
- Hjertecentrets Forskningsudvalg, Rigshospitalet
Ask authors/readers for more resources
Background: Mortality in ST-elevation myocardial infarction (STEMI) patients developing cardiogenic shock (CS) during hospitalization is high. Catecholamines, ischemia, and inflammation (parameters present in CS) affect the endothelium. We hypothesized that plasma level of biomarkers reflecting endothelial damage would be associated with CS and mortality. Methods: In 96% of 1467 consecutive patients with suspected STEMI, biomarkers reflecting endothelial cell( soluble thrombomodulin, sTM) and glycocalyx-(syndecan-1) damage were measured on admission. Patients were stratified by CS development or not. CS-Patients were substratified by CS on admission (admission-CS), CS developed in the catheterization laboratory (cath. lab.-CS), or late CS. Results: STEMI patients with admission-CS (n = 85) and cath. lab.-CS (n = 25) had higher levels of sTM and syndecan-1 compared with no-CS patients (n = 1,299). Late CS-patients (n = 58) had higher levels of sTM (median (25th; 75th percentile) 8.8 (7.0; 11.6) vs. 7.4 (6.0; 9.0) ng/mL, P = 0.0004) but not Syndecan-1 (P = 0.26) compared with no-CS patients. sTM was, however, not independently associated with late CS development (OR (95% CI) 1.07 (0.99-1.16), P = 0.09). Patients with the highest level of sTM and syndecan-1 had the highest 30-day mortality (Plogrank< 0.0001). However, neither sTM nor Syndecan-1 was independently associated with 30-day mortality (HR (95% CI) sTM: 1.06 (0.996-1.12), P = 0.07; Syndecan-1: 1.04 (0.99-1.08), P = 0.12). Conclusion: Patients with suspected STEMI patients and admission-CS/cath. lab.-CS had elevated admission levels of sTM and Syndecan-1comparedwith noCSpatients. Patients developing lateCShad higher sTMplasma concentrationcompared with patients without shock. However, the biomarker levels were not independently associated with late CS and mortality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available